Last reviewed · How we verify

HDM SLIT-tablet — Competitive Intelligence Brief

HDM SLIT-tablet (HDM SLIT-tablet) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sublingual immunotherapy (SLIT) tablet. Area: Immunology / Allergy.

phase 3 Sublingual immunotherapy (SLIT) tablet Immunology / Allergy Biologic Live · refreshed every 30 min

Target snapshot

HDM SLIT-tablet (HDM SLIT-tablet) — ALK-Abelló A/S. HDM SLIT-tablet is a sublingual immunotherapy that delivers house dust mite allergen extract to induce immune tolerance and reduce allergic responses.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HDM SLIT-tablet TARGET HDM SLIT-tablet ALK-Abelló A/S phase 3 Sublingual immunotherapy (SLIT) tablet
HDM SLIT-tablet (12 SQ-HDM) HDM SLIT-tablet (12 SQ-HDM) ALK-Abelló A/S phase 3 Sublingual immunotherapy (SLIT) tablet

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sublingual immunotherapy (SLIT) tablet class)

  1. ALK-Abelló A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HDM SLIT-tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/hdm-slit-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: